Matinas BioPharma Holdings (MTNB) Retained Earnings (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Retained Earnings of -$212.7 million for Q1 2026, down 5.57% year-over-year from -$225.3 million in Q1 2025, and down 0.91% quarter-over-quarter from -$210.8 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Retained Earnings (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Retained Earnings for 14 consecutive years, with -$212.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 5.57% year-over-year to -$212.7 million; the TTM figure through Mar 2026 stood at -$212.7 million (down 5.57% YoY), while the FY2025 annual figure was -$210.8 million, down 5.49% from the prior year.
- Retained Earnings eased to -$212.7 million in Q1 2026 per MTNB's latest filing, from -$210.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $206.2 million in Q2 2024 and bottomed at -$212.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$93.4 million across 5 years, with a median of -$175.6 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 40225.49% in 2024 and fell as far as 53212.26% in 2024.
- Matinas BioPharma Holdings' Retained Earnings stood at -$824000.0 in 2022, then slumped by 21207.4% to -$175.6 million in 2023, then retreated by 13.81% to -$199.8 million in 2024, then fell by 5.49% to -$210.8 million in 2025, then fell by 0.91% to -$212.7 million in 2026.
- Business Quant data shows MTNB's Retained Earnings at -$212.7 million in Q1 2026, -$210.8 million in Q4 2025, and -$208.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | Matinas BioPharma Holdings | 1.20 Mn | 385,676.50 | - | -214.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -214.03 Mn |
| Mar 31, 2026 | -212.71 Mn |
| Dec 31, 2025 | -210.79 Mn |
| Sep 30, 2025 | -208.88 Mn |
| Jun 30, 2025 | -206.73 Mn |
| Mar 31, 2025 | -201.48 Mn |
| Dec 31, 2024 | -199.82 Mn |
| Sep 30, 2024 | -191.39 Mn |
| Jun 30, 2024 | 206.25 Mn |
| Mar 31, 2024 | -181.40 Mn |
| Dec 31, 2023 | -175.57 Mn |
| Sep 30, 2023 | -359,000.00 |
| Jun 30, 2023 | -514,000.00 |
| Mar 31, 2023 | -595,000.00 |
| Dec 31, 2022 | -824,000.00 |
| Sep 30, 2022 | -935,000.00 |
| Jun 30, 2022 | -754,000.00 |
| Mar 31, 2022 | -629,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | 183.17 Mn |